Exchange: NASDAQ·Updated 07:58 PM EST
BNGO logo

BNGO Bionano Genomics Inc

$0.8222
$0.0628
(7.10%)
Today
Closed $0.8222
$0.0078
(0.95%)
After Hours
Reported EarningsNov 10
Mkt Cap$11.5M
Vol251,844.00

About BNGO

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
27

Bearish Sentiment

How do you feel about BNGO?

TheBioPunkRevenger
$BNGO Prenatal OGM just got a practical workflow upgrade. Peking Union study (Molecular Cytogenetics): 199 consecutive prenatal samples. OGM ran clean on inputs as low as 0.225 million amniotic fluid cells — well below standard kit recommendations. 96.9% concordance with karyotype + microarray. In 74 of the positive cases it added breakpoint resolution, orientation, and fusion detail the older stack missed. This is one of the higher-probability non-heme lines on the menu. Prenatal volume is real. Lower cell input + shorter culture time removes a friction point that has kept mapping out of many prenatal workflows. Heme 81195 is already live and paid. Constitutional 81354 is live. NYSDOH LDTs are cleared. MolDX heme draft is out. Now prenatal shows it can run on the thin samples labs actually get. Street models are still pricing mostly one heme kit. The menu keeps expanding with real clinical data. That’s the flywheel. The distribution is still wrong.
1
TheBioPunkRevenger
$BNGO $PACB PacBio Just Invited Optical Genome Mapping to the Party and Forgot to Tell Razor_Ramon Razor banned me for pointing out the obvious, so I’ll say it here: PacBio’s own LinkedIn just promoted a KU Leuven talk using optical genome mapping + long-read Fiber-seq on non-Hodgkin lymphoma. Same agenda. Complementary workflow. Multiomic. Not “LRS replaces mapping.” Baylor already stacks them. Literature keeps showing OGM catches balanced/complex SVs long-read still misses at clinical scale. Live 81195 still pays. Razor can keep the block. PacBio already put the map on the invite list. ;)
2
Toast82947
$BNGO this is about to pop again. Macd cross on daily. Bullish divergence on weekly. Something big coming and someone is loading.
2
BartDude1977
$BNGO lost 95% on this stock. Huge scam. Erik Homlin has the same initials as another biotech scammer (Elizabeth Holmes). I don’t make the rules - but that’s beautifully ironic. Stay away!
1
TheBioPunkRevenger
$BNGO From the Q3 call, Al Luderer: “Q3 2026 flow cells sold were up 18% year over year at 9,870 units, a record for any quarter. In short, our customers are processing more samples than ever and a large share of that added volume comes from laboratories bringing OGM into routine use.” Consumables $4.7M (+24%). Gross margin 48%. Opex down. $31–33M guide reaffirmed. NYSDOH approvals at Rochester + MSK. MolDX proposed LCD covers 31 states for genome-wide SV detection in heme. Clearer Medicare path. Easier for labs to go routine. On path: “Our main focus for ’27 is going to be to bring this company to EBITDA neutral so that we can move into 2028 in a highly profitable mode.” Adjusted EBITDA neutrality by end of 2027. Record chips. Routine use. Paid map. Still priced like a kit.
1
StocktwitsEarnings
$BNGO Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.55 up 65.41% YoY • Reported revenue of $8.28M up 12.35% YoY • Bionano reiterated full year 2026 revenue guidance in the range of $31 to $33M; no quantified margin or earnings guidance appears in the 2026 outlook.
1
vaccigen
$BNGO did the dasholes announce the next reverse split date during the earnings? If they didn't, don't be disappointed, they will soon. People should donate more dollars so they can pay their salaries and perks for next one year.
geistvonspiez
$BNGO in a nutshell: 🔬 World-class technology (OGM adoption growing) ⏳ Reimbursement timeline: 2-4 years to full standard-of-care 💸 Cash burn vs. runway is the key risk ​The tech is real, but cash is running out very soon. So more dillution or a buyer is making good business.

Advertisement|Remove ads.